dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Gonzalez, David |
dc.contributor.author | Mateo Valderrama, Joaquim |
dc.contributor.author | Stenzinger, Albrecht |
dc.contributor.author | Rojo, Federico |
dc.contributor.author | Shiller, Michelle |
dc.contributor.author | Wyatt, Alexander W |
dc.date.accessioned | 2022-03-14T12:29:50Z |
dc.date.available | 2022-03-14T12:29:50Z |
dc.date.issued | 2021-07 |
dc.identifier.citation | Gonzalez D, Mateo J, Stenzinger A, Rojo F, Shiller M, Wyatt AW, et al. Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. J Pathol Clin Res. 2021 Jul;7(4):311–25. |
dc.identifier.issn | 2056-4538 |
dc.identifier.uri | https://hdl.handle.net/11351/7157 |
dc.description | Reparació per recombinació homòloga; Càncer de pròstata metastàtic; Inhibidors de la poli(ADP-ribosa) polimerasa |
dc.description.sponsorship | JM has served on advisory boards for Amgen, AstraZeneca, Clovis Oncology, Janssen, Merck/MSD, and Roche; has participated in speaker bureaus for AstraZeneca, Pfizer, Janssen, Sanofi, and Astellas Pharma; and has received research funding from AstraZeneca and Pfizer Oncology through grants to his institution. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | The Journal of Pathology: Clinical Research;7(4) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pròstata - Càncer - Tractament |
dc.subject | Metàstasi |
dc.subject | ADN - Reparació |
dc.subject.mesh | Prostatic Neoplasms, Castration-Resistant |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Recombinational DNA Repair |
dc.subject.mesh | /genetics |
dc.title | Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/cjp2.203 |
dc.subject.decs | neoplasias prostáticas resistentes a la castración |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | reparación del ADN por recombinación |
dc.subject.decs | /genética |
dc.relation.publishversion | https://doi.org/10.1002/cjp2.203 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Gonzalez D] Patrick G Johnston Centre for Cancer Research, Queen’s University, Belfast, UK. [Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Stenzinger A] Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. [Rojo F] Department of Pathology, IIS-Hospital Universitario Fundación Jiménez Díaz-CIBERONC, Madrid, Spain. [Shiller M] Department of Pathology, Baylor University Medical Center, Dallas, TX, USA. [Wyatt AW] Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada |
dc.identifier.pmid | 33630412 |
dc.identifier.wos | 000621550600001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |